Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Certolizumab Combo Helps Curb RA Damage

David Douglas  |  June 15, 2016

“Overall,” Dr. Hazlewood concludes, “the impact on RA management will be small, as biologic therapy is rarely if ever used as first-line treatment.”

UCB Pharma sponsored the study. A number of authors including Dr. Emery have relationships with UCB Pharma, and several are employed by the company.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Page: 1 2 | Single Page
Share: 

Filed under:Drug Updates Tagged with:Certolizumab Pegolcombination therapyDisease-modifying antirheumatic drugs (DMARDs)MethotrexateRheumatoid Arthritis (RA)

Related Articles
    Rheumatoid Arthritis Research Provides New Insights on Risk Factors, Identification Tools, Intervention

    Rheumatoid Arthritis Research Provides New Insights on Risk Factors, Identification Tools, Intervention

    October 11, 2016

    Established wisdom holds that patients with rheumatoid arthritis (RA) will fare better if their disease is diagnosed as early as possible, and treatments with disease-modifying drugs are started before inflammation can do more damage to joints and tissue. Usually, early diagnosis means spotting the clinical signs of disease, but new research tells us more about…

    California Rheumatology Alliance 2013 Meeting: The Future of Rheumatoid Arthritis

    July 1, 2013

    Treatment for RA should involve targeting subclinical disease and reversing immune dysregulation, expert says

    Certolizumab Pegol Usage Compatible with Breastfeeding

    December 20, 2016

    In a small-scale study, researchers found that no, or minimal amounts of, certolizumab pegol transfers from mothers taking the drug to nursing infants…

    California Rheumatology Alliance 2013 Meeting: Aim for Remission in Rheumatoid Arthritis

    July 1, 2013

    Early diagnosis and aggressive treatment of RA is key, expert says

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences